Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer

(marketscreener.com) Updated data from the phase 2 clinical trial of CAN-2409 in non-small cell lung cancer showing disease control rate of 77 percent in patients entering the study with progressive disease, translating into preliminary evidence of improved progression-free survivalHighlighted effects of a single injection of CAN-3110 in recurrent high-grade glioma ...https://www.marketscreener.com/quote/stock/CANDEL-THERAPEUTICS-INC-125090831/news/Candel-Therapeutics-R-D-Day-Presentations-Spotlight-its-Advanced-Pipeline-and-Capabilities-to-Develo-42489874/?utm_medium=RSS&utm_content=20221206